Financial Data and Key Metrics Changes - In Q4 2025, the company achieved organic constant currency sales growth of 5.4%, with total net sales reaching $2.244 billion, a 10.9% increase on a reported basis [15][16] - Adjusted earnings per share (EPS) for Q4 was $2.42, up 4.8% year-over-year, despite dilution from the Paragon 28 transaction and tariff impacts [15][17] - For the full year 2025, organic constant currency sales grew by 3.9%, with adjusted EPS of $8.20 and free cash flow of $1.172 billion, marking over 11% growth year-over-year [15][19] Business Line Data and Key Metrics Changes - The U.S. business grew by 5.7% on an organic constant currency basis, driven by new product momentum and strong robotic sales [15][16] - The hips franchise saw nearly 8% growth in the U.S., with the Z1 implant representing over 35% of U.S. hip stems [6][7] - The cranio-maxillofacial thoracic business grew mid-teens in the quarter, while upper extremities experienced high single-digit growth [7] Market Data and Key Metrics Changes - International revenue grew by 5% on an organic constant currency basis, supported by new product momentum and strong robotic sales [15][16] - The U.S. NEE growth was 6% in the quarter, driven by increased penetration of the Persona OsseoTi knee [6] Company Strategy and Development Direction - The company is transitioning to a dedicated and specialized U.S. sales channel to drive consistent growth, with expectations for completion by the end of 2027 [8][9] - Strategic priorities include enhancing people and culture, operational excellence, and innovation and diversification [10][12] - The company plans to prioritize returning capital to shareholders over M&A, with a buyback program of up to $1.5 billion approved [88][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving low single-digit organic constant currency revenue growth for 2026, with adjusted EPS guidance of $8.30-$8.45 [20][22] - The transition of the U.S. sales force is expected to create short-term disruptions but is deemed essential for long-term sustainable growth [32][83] - Management highlighted the importance of new product adoption and international performance as key factors influencing future growth [38][39] Other Important Information - The company reported a negative pricing impact of 50 basis points in Q4, with expectations of up to 100 basis points of pricing erosion in 2026 [16][42] - Adjusted gross margin for Q4 was 72.4%, with expectations for a decline in gross margins for 2026 due to lower revenue growth and pricing pressures [17][70] Q&A Session Summary Question: Salesforce optimization initiatives impact - Management explained the transition to a dedicated sales force is aimed at improving productivity and leveraging new products, with expected benefits by the end of 2027 [28][32] Question: Guidance for 2026 and sales transition - Management indicated that the guidance reflects uncertainties related to the sales force transition, new product adoption, and international performance [36][38] Question: Pricing erosion outlook - Management noted that pricing is expected to remain under pressure due to market conditions and specific regional factors, including Japan's biannual price decrease [42][43] Question: Paragon 28 contribution to growth - Management acknowledged that Paragon 28's contribution was slightly below expectations but remains committed to achieving double-digit growth in 2026 [76][77] Question: Confidence in Salesforce transition - Management emphasized data-driven decisions and benchmarking against competitors as the basis for confidence in the sales force transition [81][83]

Financial Data and Key Metrics Changes - In Q1 2025, Zimmer Biomet reported net sales of $1.909 billion, reflecting a 1.1% increase on a reported basis and a 2.3% increase excluding foreign currency impact [27] - Adjusted earnings per share (EPS) for the quarter was $1.81, down from $1.94 in the prior year, attributed to higher costs and investments [32] - The company generated $279 million in free cash flow, demonstrating robust growth compared to the previous year [26] Business Line Data and Key Metrics Changes - U.S. hips sales grew nearly 4%, while U.S. knees saw a modest growth of 0.2% [29] - The S.E.T. segment grew by 4.9%, with notable growth in CMFT and Sports categories [30] - International sales grew by 3.7%, driven by mid-single digit growth in knees and high-single digit growth in S.E.T. [28] Market Data and Key Metrics Changes - The U.S. market showed a 1.3% growth overall, with hips and S.E.T. driving performance [27] - Internationally, hips grew by 2.4%, with U.S. hips growing at 3.7% and international hips at 1% [29] - The company anticipates a full-year organic constant currency revenue growth of 3% to 5% for 2025 [10] Company Strategy and Development Direction - Zimmer Biomet is focusing on three strategic priorities: people and culture, operational excellence, and innovation and diversification [12] - The company aims to enhance its U.S. market performance through leadership changes and optimizing sales channels [14] - The recent acquisition of Paragon 28 is expected to contribute approximately 270 basis points to sales growth in 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the full-year guidance despite challenges such as tariffs and foreign exchange impacts [34] - The company is optimistic about new product launches and expects second-half growth to be higher than the first half due to favorable comparisons and new product uptake [35] - Management acknowledged the need for improved performance in the U.S. knee segment and is implementing strategies to enhance competitiveness [81] Other Important Information - The company reported a reduction in days on hand inventory from over 400 days in early 2024 to approximately 370 days [15] - The Paragon 28 acquisition was successfully integrated with minimal disruption, retaining key leadership and sales teams [110] Q&A Session Summary Question: Impact of tariffs on EPS and mitigation efforts - Management detailed steps taken to mitigate tariff impacts, including optimizing country of origin and sourcing adjustments, expecting a $60 million to $80 million headwind for 2025 [45][46] Question: Growth expectations and new product impacts - Management indicated confidence in achieving mid-single digit growth in the second half of 2025, driven by new product launches and improved execution [56][57] Question: Performance in ASC versus hospital channels - The company noted that over 20% of U.S. sales now come from the ASC environment, with expectations for continued growth in this area [94] Question: Pricing trends and future expectations - Management expects pricing to remain flat for 2025, with a stable environment compared to historical norms, despite previous fluctuations [68][69] Question: Clarification on the Paragon acquisition integration - The integration of Paragon 28 is progressing well, with all key personnel retained and ongoing product innovations maintained [110]